CRYOFOCUS MEDTECH (SHANGHAI) CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.4 HKD | 0.00% |
|
+3.06% | -65.99% |
| Mar. 27 | Cryofocus Medtech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 15 | Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,729 | 4,090 | 1,420 | - | - |
| Enterprise Value (EV) 1 | 3,729 | 4,090 | 1,420 | 1,420 | 1,420 |
| P/E ratio | - | -41.7 x | -20.8 x | -98.9 x | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 137 x | 99.9 x | 8.28 x | 4.05 x | 2.4 x |
| EV / Revenue | 137 x | 99.9 x | 8.28 x | 4.05 x | 2.4 x |
| EV / EBITDA | - | -39.2 x | -25.1 x | 349 x | 11.9 x |
| EV / FCF | - | - | -16.2 x | -51.2 x | 23.8 x |
| FCF Yield | - | - | -6.16% | -1.95% | 4.2% |
| Price to Book | - | - | 17.5 x | 20.5 x | - |
| Nbr of stocks (in thousands) | 239,110 | 239,110 | 239,110 | - | - |
| Reference price 2 | 15.60 | 17.11 | 5.937 | 5.937 | 5.937 |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 27.15 | 40.95 | 171.5 | 350.5 | 591.4 |
| EBITDA 1 | - | -104.4 | -56.49 | 4.07 | 119.7 |
| EBIT 1 | - | -105.1 | -71 | -15.15 | 99.4 |
| Operating Margin | - | -256.64% | -41.4% | -4.32% | 16.81% |
| Earnings before Tax (EBT) 1 | - | -105.7 | -71.64 | -15.85 | - |
| Net income 1 | -112.2 | -97.49 | -67.94 | -15.04 | - |
| Net margin | -413.36% | -238.06% | -39.62% | -4.29% | - |
| EPS 2 | - | -0.4100 | -0.2850 | -0.0600 | - |
| Free Cash Flow 1 | - | - | -87.44 | -27.72 | 59.61 |
| FCF margin | - | - | -50.99% | -7.91% | 10.08% |
| FCF Conversion (EBITDA) | - | - | - | - | 49.79% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -87.4 | -27.7 | 59.6 |
| ROE (net income / shareholders' equity) | - | - | -47.2% | -13.1% | - |
| ROA (Net income/ Total Assets) | - | - | -30.3% | -6.65% | - |
| Assets 1 | - | - | 224.1 | 226.3 | - |
| Book Value Per Share 2 | - | - | 0.3400 | 0.2900 | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 15.9 | 29.7 | 33.9 |
| Capex / Sales | - | - | 9.28% | 8.48% | 5.73% |
| Announcement Date | 3/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.937
CNY
Average target price
25.57
CNY
Spread / Average Target
+330.74%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -65.99% | 196M | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.32% | 238B | |
| +7.12% | 204B | |
| -5.93% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- 6922 Stock
- Financials Cryofocus Medtech (Shanghai) Co., Ltd.
